Becton Dickinson (BDX) 2025 Earnings Quality Report

Grade: D — Leveraged Acquisitions Meet a Planned Separation

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2025-11-25, fiscal year ended September 30, 2025) + Yahoo Finance

Auditor: Ernst & Young LLP — Clean opinion (1 Critical Audit Matter)

One-line verdict: BD grew revenue 8.2% to $21.84B in 2025, driven substantially by the $4.2B Edwards Lifesciences Critical Care acquisition completed September 3, 2024. Cash flow is reasonable ($3.43B CFFO, 2.04x of net income) and core profitability is intact (gross margin 45.4%, net income $1.68B), but the balance sheet has absorbed significant damage. Cash of just $641M covers only 3% of $19.2B in total debt — the C4 check failed by the widest margin in this batch. Goodwill plus intangibles of $36.0B equal 142% of stockholders' equity of $25.4B. The F-Score fraud probability of 0.31% is among the lowest in this batch, the M-Score of -2.64 is comfortably below the manipulation threshold, and EY has audited the company since 1959 (66 years) without incident. The Altman Z-Score of 2.28 sits in the grey zone — not distress, but not safe. BD's strategic response to the leverage problem is itself in the 10-K: the planned separation and combination of the Biosciences and Diagnostic Solutions business with Waters Corporation, announced in July 2025 and effective after a Reverse Morris Trust structure. Until that deal closes, the current capital structure is the structure shareholders are underwriting.

Business: Three Segments, Transitioning to Five

Per Item 1 of the 10-K: "As of September 30, 2025, BD's operations consisted of three worldwide business segments: BD Medical, BD Life Sciences and BD Interventional. As further discussed in Note 8 to the consolidated financial statements contained in Item 8... effective October 1, 2025, BD reorganized its organizational units into five distinct, separately-managed segments, based on the nature of BD's product and service offerings. BD's new organizational structure is based upon the following five segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences."

The 10-K discloses the planned separation: "Life Sciences, which remains a critical part of BD until the separation and combination of our Biosciences and Diagnostic Solutions business with Waters Corporation ('Waters'), as further discussed below, is completed."

Segment revenue breakdown per the segment note:

BD Medical is the largest segment, led by Medication Delivery Solutions (IV catheters, port access, needle-free connectors), Medication Management Solutions, Diabetes Care, and the newly acquired Advanced Patient Monitoring business.

The Edwards Critical Care Acquisition

Per the 10-K Item 1: "On September 3, 2024, BD completed the acquisition of Edwards Lifesciences Critical Care product group, which was renamed as BD Advanced Patient Monitoring. The fair value of consideration transferred in connection [with the acquisition]..." was approximately $4.2B.

Per the cash flow statement, purchase of business in FY2024 was -$3,924M — essentially this transaction. The acquired product line includes "Advanced hemodynamic monitoring systems used to measure a patient's heart function and fluid status in surgical and intensive care settings, including noninvasive tissue oximetry systems; hemodynamic and tissue oximetry monitoring systems; pulmonary artery catheters and arterial pressure monitoring products and blood pressure measurement systems."

The deal explains the jump in goodwill (from $24.5B to $26.5B), the $4.2B of new debt on the balance sheet, and the FY2025 revenue growth of 8.2% against FY2024 growth of 4.2%.

Profitability: Stable But Carrying Interest

Per the consolidated statements of operations:

Gross margin of 45.4% is stable YoY (+0.2pp) and passes B4. R&D is flat in absolute dollars, which is notable for a medical technology company but does not flag the screen. SG&A grew 8.7%, roughly in line with revenue.

The key trend line is interest expense: $452M → $528M → $613M. That is +36% over two years, reflecting the Edwards debt raise. Every incremental dollar of interest comes out of net income, and net income in FY2025 was actually $27M lower than FY2024 despite the revenue growth and EBITDA improvement — because interest expense grew by $85M year-over-year.

Cash Flow: Still Strong

Per the consolidated statements of cash flows:

CFFO of $3.43B covers net income of $1.68B at 2.04x — a very strong ratio. FCF of $2.67B funds the $1.20B dividend with over $1.4B to spare. C1 and C2 both pass comfortably. Accruals ratio of -3.2% is low (C3 pass).

The underlying earnings power of the business is much larger than reported net income suggests — the gap is driven by intangible amortization from the decades of acquisitions (CR Bard 2017, Bard Davol, Embecta spin-off in 2022, Edwards Critical Care 2024).

The Leverage Problem: C4 Fails Badly, D1 Fails

This is where the screen flags BDX. Per the balance sheet:

C4 FAIL: Cash of $641M covers only 3% of total debt of $19.18B. This is the lowest cash coverage in this batch. BD's cash position has dropped from $1.72B a year ago — the drop coincides with accelerated debt repayment and the dividend increase from $1.10B to $1.20B.

D1 FAIL: Goodwill plus intangibles of $36.0B equal 142% of stockholders' equity of $25.4B. BDX's balance sheet is overwhelmingly intangible assets from decades of acquisitions. If even 20% of this were impaired, equity would drop materially.

D2 PASS: Debt/EBITDA of 3.9x is below the 4.0x threshold, but just barely. At FY2024 it was 4.2x.

The 10-K's announced Biosciences/Waters separation is explicitly designed to address this. Biosciences and Diagnostic Solutions would be separated from BD and combined with Waters Corporation in a Reverse Morris Trust transaction. BD would receive cash consideration (rumored at approximately $17.5B from various public sources), which would allow substantial debt paydown and capital return to shareholders. Until the transaction closes, BD remains in the current state.

The 18-Point Screening

Beneish M-Score components: DSRI 0.912 (very good, declining), GMI 0.995, AQI 1.012, SGI 1.082 (moderate growth), DEPI 0.964, SGAI 1.004, TATA -0.0317, LVGI 0.998.

All components are in the normal range. The DSRI of 0.912 is notable because it is below 1.0 — receivables declined relative to sales, the opposite of the A2 flag we saw in ABT and ALGN. BD's working capital management is tight.

Altman Z-Score 2.28: grey zone. Components: X1 working capital/assets 0.01, X2 retained earnings/assets 0.37, X3 EBIT/assets 0.04, X4 equity/liabilities 0.85. The X1 (working capital) is notably low because of the large current debt component, and X4 is weighed down by the $19B debt load.

F-Score 0.57 — fraud probability 0.31%, one of the lowest in the group. BD is not hiding anything accounting-wise.

Key Risks from the 10-K (Item 1A)

1. The Waters Separation Execution Risk

The planned separation of Biosciences and Diagnostic Solutions from BD and combination with Waters Corporation is the single most important strategic event in the 10-K. Reverse Morris Trust transactions are structurally complex, require shareholder approval from both companies, regulatory clearance, and tax ruling confirmation. Any delay or termination would leave BD carrying the current debt load indefinitely.

2. Debt Service and Refinancing

Interest expense has grown 36% over two years to $613M. BD's weighted average cost of debt has climbed with both the acquisition-driven debt raise and rising interest rates. Refinancing maturing senior notes at prevailing rates will further pressure net income.

3. Single-Supplier and Manufacturing Concentration

As a large medical device manufacturer, BD operates global facilities where disruption risk is significant. The 10-K discusses these risks in Item 1A along with regulatory, quality, and FDA inspection exposure.

4. Uncertain Tax Positions

EY's Critical Audit Matter identifies the CAM as Uncertain tax positions: "The Company has recorded a liability of $285 million related to uncertain tax positions as of September 30, 2025... Due to the inherent uncertainty in predicting the resolution of these tax matters, auditing the Company's uncertain tax positions involved complex analysis and auditor judgment."

$285M is approximately 17% of net income — not as large as Abbott's $4.0B UTB balance but still material.

5. Pricing and GPO Contracts

Hospital purchasing has concentrated through GPOs over the last decade. BD's largest product lines (IV catheters, port access, infusion pumps) are commodity-adjacent and face ongoing pricing pressure.

Auditor's Critical Audit Matter

Per the audit report: "As discussed in Notes 1 and 17 to the consolidated financial statements, the Company conducts business in numerous countries and as a result, files tax returns in those locations. Uncertain tax positions may arise for multiple reasons including, but not limited to, the interpretation of global tax rules and regulations. The Company uses judgment to (1) determine whether, based on the technical merits, a tax position is more likely than not to be sustained and (2) measure the amount of tax benefit that qualifies for recognition. The Company has recorded a liability of $285 million related to uncertain tax positions as of September 30, 2025. Due to the inherent uncertainty in predicting the resolution of these tax matters, auditing the Company's uncertain tax positions involved complex analysis and auditor judgment."

EY has served as BD's auditor since 1959 — 66 consecutive years, the longest tenure in this batch. That is a structural relationship that has seen BD through multiple business cycles and strategic reorganizations.

Key Financial Trends (4-Year)

Summary

Grade: D. Two balance-sheet red flags on a company whose operating fundamentals remain solid.

BD's earnings quality screen is generally clean. All the accrual-based checks (A1-A3, B1-B4) pass, all the cash flow checks (C1-C3) pass, the Beneish M-Score of -2.64 is below the manipulation threshold, and the F-Score fraud probability is 0.31% — one of the lowest in the group. EY has audited the company for 66 years and issued a clean opinion. CFFO of $3.43B at 2.04x of net income confirms earnings are cash-backed.

The two failures are both on the balance sheet:

Both failures trace back to the Edwards acquisition and the underlying M&A strategy. BD's response is in the 10-K: the planned Biosciences/Waters Corporation separation will materially deleverage the balance sheet when it closes. Until then, the Altman Z-Score of 2.28 sits in the grey zone, interest expense has grown 36% over two years to $613M, and net income was $27M lower in FY2025 than FY2024 despite the revenue growth.

This is a capital-structure grade, not an operating grade. The business generates $3.4B of operating cash flow and $2.7B of free cash flow against $1.2B of dividends — genuinely strong. But the screen's mandate is to flag risk, and the balance sheet is the risk.

Read the 10-K. Read the Waters separation disclosure. Read Note 17 on uncertain tax positions. Then decide whether the separation mechanics and timeline make the 3% cash coverage tolerable.

**Disclaimer**: This report is based on Becton Dickinson's fiscal year 2025 10-K filed with the SEC on November 25, 2025. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade D means material concerns were identified that warrant investigation.